It can also affect blood sugar levels and contribute to dehydration
By activating these receptors, tirzepatide: Enhances glucose-dependent insulin secretion from pancreatic beta cells, reducing blood glucose levels without causing hypoglycaemia when glucose levels are normal (though risk increases when used with insulin or sulfonylureas) Suppresses glucagon release from pancreatic alpha cells, further improving glycaemic control Slows gastric emptying , which moderates postprandial glucose excursions, though this effect may diminish over time due to tachyphylaxis Reduces appetite and food intake through central nervous system pathways, contributing to significant weight loss Tirzepatide is administered once weekly via subcutaneous injection, with doses typically titrated from 2
Reconstituted Material: Once reconstituted, researchers generally store solutions under refrigerated conditions and utilise them within suitable laboratory timeframes
It cannot be used with government-funded coverage
NICE recommends continuing only if specific HbA1c and weight reduction targets are met at 6 months
Mounjaro (tirzepatide) operates by mimicking a couple of natural hormones, GLP-1 and GIP
